I understand all of that. I don't see how you can make a rationale for that being positive for Ponatinib. Are you arguing that Ponatinib will be approved for 2nd line in the UK, while the other drugs will not be approved? That's a real stretch, IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.